INVESTIGATIVE REPORT

Lack of Association of CCR4 Single Nucleotide Polymorphism with Atopic Dermatitis in Japanese Patients

Yuichiro TSUNEMI1, Takashi SEKIYA2, Hidehisa SAEKI1, Koichi HIRAI2, Ken OHTA3, Koichiro NAKURA4, Takashi KAKUNUMA1, Hideki FUJITA1, Shinji KAGAMI1, Noriko ASANO1, Yuka TANIDA1, Motoshi WAKUGAWA1, Hideshi TORII1 and Kunihiko TAMAKI1

Departments of 1Dermatology and 2Allergy and Rheumatology, Faculty of Medicine, University of Tokyo, 3Department of Internal Medicine, Faculty of Medicine, Teikyo University, Tokyo and 4Department of Dermatology, Fukushima Medical University School of Medicine, Fukushima, Japan

CCR4, a member of the CC chemokine receptor family, is believed to play an important role in the pathogenesis of atopic dermatitis. To examine whether CCR4 single nucleotide polymorphism (SNP) is associated with susceptibility to atopic dermatitis, we investigated the allele and genotype frequencies of C1014T SNP of CCR4 in 198 Japanese patients with atopic dermatitis and controls by a PCR-restriction fragment length polymorphism method. There was no significant difference in allele or genotype frequencies between patients with atopic dermatitis and controls. Serum IgE levels and peripheral blood eosinophil counts were not significantly different among genotypes. There was also no significant difference in allele or genotype frequencies between the patient subgroup with and without asthma, with mild or moderate disease, with and without family history of atopic dermatitis, or with and without family history of atopic disorders. C1014T SNP of CCR4 does not appear to be associated with susceptibility to atopic dermatitis in Japanese patients. Key words: atopic dermatitis; CCR4; single nucleotide polymorphism.

(Accepted December 12, 2003.)


Yuichiro Tsunemi, Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: ytsun-tky@umin.ac.jp

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease associated with elevated serum IgE levels and tissue and peripheral blood eosinophilia (1), and is characterized by expansion of Th2 cells and a decrease of Th1 cells, at least in the initial stages (1, 2). The pathogenesis of AD involves various cytokines, chemokines and their receptors (1).

CCR4 is a member of the CC chemokine receptor family (3–5). It was shown to be predominantly expressed on Th2 lymphocytes, eosinophils and basophils (3–9), and is a receptor for two chemokines, thymus and activation-regulated chemokine (TARC) (10) and macrophage-derived chemokine (MDC) (11), which act specifically on activated Th2 lymphocytes (4, 5, 7–9).

Recent studies indicated that TARC, MDC and CCR4 play a vital role in the pathogenesis of AD, inducing Th2 response by attracting CCR4+ Th2 cells to the lesional skin (12–20).

The biological activities of CCR4 could indicate that polymorphism of CCR4 is a candidate as one of the genetic factors in AD. Variations in CCR4 have been reported (21), including silent mutations: G498C (V166V), C1014T (Y338Y) and missense mutations: C388G (L130V), G533C (C178S) (counting from the ATG start codon). While variations other than C1014T are rare in the Japanese population, the frequency of 1014T allele was reported to be 3.6% (21), and this variation was considered a single nucleotide polymorphism (SNP).

In this study, we examined whether this SNP in CCR4 is associated with susceptibility to AD in Japanese patients using case-control analysis. We also compared the allele and genotype frequencies between patient subgroups with and without asthma, with mild or with moderate disease and with and without a family history of AD or any type of atopic disorders.

MATERIALS AND METHODS

We evaluated 198 unrelated Japanese patients with AD who were diagnosed according to the generally accepted criteria of Hanifin and Rajka (22). The patient group consisted of 139 male and 59 female subjects, aged 11–61 years (mean ± SD, 27.4 ± 7.7) with serum IgE levels in the range of 5–84 000 U/ml (median [interquartile range]: 7000 [1600–15 000]) and peripheral blood eosinophil counts in the range of 0–2246/μl (421 [271–649]). IgE levels and peripheral blood eosinophil counts were examined prior to therapies. One hundred and eighty-three Japanese individuals served as control subjects: 104 male and 79 female subjects, aged 18–82 years (29.2 ± 13.4).

Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp blood kit (Qiagen, Hilden, Germany). Genotyping was carried out by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. We amplified the region of CCR4, which includes a SNP site C1014T, by PCR using a set of specific primers: 5′-TGTTGGCTCCTCAAATGTA-3′ (sense: 1011T > G, mismatch primer) and 5′-TGTAAGCCTTCCTC CTGACA-3′ (antisense). A mismatch primer was used to
create the RsI restriction endonuclease polymorphism site. The SNP site was detected by digestion with RsI. The PCR product was 206 bp. The product from 1014C allele was cut into 187- and 19-bp fragments while that of 1014T allele was uncut and remained 206 bp.

We compared the allele and genotype frequencies between patients with AD and controls, and compared serum IgE levels and peripheral blood eosinophil counts among genotypes in the patients with AD. We also compared the allele and genotype frequencies between patients with AD and those with asthma and those without asthma (information about asthma coexisted or not was available in 134 patients with AD). Asthma was diagnosed according to accepted criteria (23). Comparison was also made of the allele and genotype frequencies between patients with AD with mild disease (SCORAD<15) (24, 25) and those with moderate disease (15<SCORAD<40), between those with a family history of AD and those without it, and between those with a family history of atopic disorders (AD, asthma, allergic rhinitis, allergic conjunctivitis or pollinosis) and those without it (information about disease severity, family history of AD and that of atopic disorders was available in 71, 114 and 81 patients with AD, respectively). There was no patient with SCORAD>40, which is severe AD.

Statistical significance was determined by χ² test (with Yates' correction if necessary) for differences of allele and genotype frequencies, and by Mann–Whitney’s U test for differences of serum IgE levels and peripheral blood eosinophil counts among genotypes.

All studies were approved by the ethics committee for genome research of the Faculty of Medicine, University of Tokyo. All patients and controls involved gave written informed consent for the genetic studies.

RESULTS

The frequencies of allele and genotype at C1014T SNP are listed in Tables I and II. There was no significant difference between patients with AD and controls. There was also no significant difference in serum IgE levels or peripheral blood eosinophil counts among genotypes (Table I). We then compared the allele and genotype frequencies between patients with AD with asthma and those without asthma, and found no difference between the two subgroups (Table II). Nor was any significant difference observed in allele or genotype frequencies between patients with AD with mild disease and those with moderate disease, between those with a family history of AD and those without it, or between those with a family history of atopic disorders and those without such history (Table II).

DISCUSSION

C1014T SNP is located at the C-terminal tail of the CCR4. The functional effect of the SNP has not been studied. The function of the CCR4 will not be affected by this SNP because this is a synonymous substitution.

### Table I. Genotype frequencies of C1014T SNP of CCR4 in patients with atopic dermatitis (AD) and control subjects, and serum IgE levels and peripheral blood eosinophil counts in each genotype in patients with AD

<table>
<thead>
<tr>
<th>Genotype</th>
<th>AD (n=198)</th>
<th>Control (n=183)</th>
<th>P value</th>
<th>Serum IgE* (IU/ml)</th>
<th>P value</th>
<th>Eosinophil counts* (µl)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C/C</td>
<td>188 (94.9)</td>
<td>173 (94.5)</td>
<td>0.58</td>
<td>7700 [1700–15700]</td>
<td>0.18</td>
<td>421 [270–650]</td>
<td>0.84</td>
</tr>
<tr>
<td>C/T</td>
<td>9 (4.5)</td>
<td>10 (5.5)</td>
<td></td>
<td>3100 [1400–5200]</td>
<td></td>
<td>420 [299–653]</td>
<td></td>
</tr>
<tr>
<td>T/T</td>
<td>1 (0.5)</td>
<td>0 (0.0)</td>
<td></td>
<td>35</td>
<td></td>
<td>493</td>
<td></td>
</tr>
</tbody>
</table>

No significant differences were found. Numbers in parentheses are percentages. C/C, C/T and T/T are the subjects who have C/C, C/T or T/T genotype at the position of 1014 in CCR4, respectively.

*Median [interquartile range].

### Table II. Analysis of association of allele and genotype frequencies with asthma, disease severity, or family history of atopic dermatitis (AD) or atopic disorders in C1014T SNP in CCR4

<table>
<thead>
<tr>
<th>AD (total) n (%)</th>
<th>Asthma n (%)</th>
<th>Severity n (%)</th>
<th>Family history of AD n (%)</th>
<th>Family history of atopic disorders, n (%)</th>
<th>Control n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(P value)</td>
<td>Yes</td>
<td>No</td>
<td>Mild</td>
<td>Moderate</td>
<td>Yes</td>
</tr>
<tr>
<td>C/C</td>
<td>188 (94.9)</td>
<td>71 (100.0)</td>
<td>56 (88.9)</td>
<td>33 (91.7)</td>
<td>33 (94.3)</td>
</tr>
<tr>
<td>C/T</td>
<td>9 (4.5)</td>
<td>0 (0.0)</td>
<td>7 (11.1)</td>
<td>3 (8.3)</td>
<td>2 (5.7)</td>
</tr>
<tr>
<td>T/T</td>
<td>1 (0.5)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>C</td>
<td>385 (97.2)</td>
<td>142 (100.0)</td>
<td>119 (94.4)</td>
<td>69 (95.8)</td>
<td>68 (97.1)</td>
</tr>
<tr>
<td>T</td>
<td>11 (2.8)</td>
<td>0 (0.0)</td>
<td>7 (5.6)</td>
<td>3 (4.2)</td>
<td>2 (2.9)</td>
</tr>
</tbody>
</table>

C and T mean the subjects who have C or T allele at the position of 1014 in CCR4, respectively. C/C, C/T and T/T mean the subjects who have C/C, C/T or T/T genotype at the position of 1014 in CCR4, respectively. P values were calculated by χ² test with Yates’ correction in 2×2 contingency table (vs control). No significant difference was found.
There is, however, a possibility that the substitution of the nucleotide in mRNA might lead to a change of mRNA stability. This SNP might, therefore, be a susceptibility gene for AD.

The results of this study show that C1014T SNP of CCR4 is not associated with susceptibility to AD, at least in Japanese patients. We also examined the association of this SNP with AD subgroups with and without asthma, with mild diseases and moderate disease, with and without a family history of AD, and with and without a family history of atopic disorders, but observed no association there either. Indeed, there is a possibility that the association could not be detected due to the lower power of this study because only 198 patients with AD and 183 controls were included, and the frequency of the 1014T allele was low in these subjects (2.7%). However, when we estimated the statistical significance for a larger sample size (power calculation), P value would reach 0.05 if the sample size for both the patients and healthy individuals were increased 2609-fold. Thus there is very little possibility that the lower power of this study was the reason we were unable to detect the association. We also found that C1014T SNP demonstrated no significant association with asthma in the Japanese population (manuscript in preparation). CCR4 SNP seems not to play a role in the pathogenesis of allergic diseases in the Japanese population. It would be of interest if the same study could be performed in patients with AD in other populations.

Kato et al. reported that the frequency of 1014T allele was 3.6% (22/608) in healthy individuals (21). In this study, the frequency was 2.7% (10/366). There is no significant difference between these two frequencies (P = 0.45). Putting the results together, the frequency of 1014T allele in Japanese population would be 3.3% (32/974).

REFERENCES